Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months…
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04…
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December…
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in…
RALEIGH, N.C., Dec. 2, 2025 /PRNewswire/ -- Avetra, a next-generation Contract Research Organization (CRO), today announced its official launch, introducing…
SAN FRANCISCO, Dec. 2, 2025 /PRNewswire/ -- Over the past few months, there has been some curiosity about CoVet's long-term direction.…
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal…
Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10,…
Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA,…
Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding…